- Home
- PIII vs ANTX Comparison
PIII vs ANTX Comparison
Compare PIII & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- ANTX
- Stock Information
- Founded
- PIII 2015
- ANTX 2017
- Country
- PIII United States
- ANTX United States
- Employees
- PIII N/A
- ANTX N/A
- Industry
- PIII Medical/Nursing Services
- ANTX Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- ANTX Health Care
- Exchange
- PIII Nasdaq
- ANTX Nasdaq
- Market Cap
- PIII 28.6M
- ANTX 31.4M
- IPO Year
- PIII N/A
- ANTX 2022
- Fundamental
- Price
- PIII $8.38
- ANTX $1.28
- Analyst Decision
- PIII Strong Buy
- ANTX Buy
- Analyst Count
- PIII 3
- ANTX 2
- Target Price
- PIII $17.50
- ANTX $2.00
- AVG Volume (30 Days)
- PIII 7.0K
- ANTX 110.6K
- Earning Date
- PIII 11-11-2025
- ANTX 11-12-2025
- Dividend Yield
- PIII N/A
- ANTX N/A
- EPS Growth
- PIII N/A
- ANTX N/A
- EPS
- PIII N/A
- ANTX N/A
- Revenue
- PIII $1,461,823,000.00
- ANTX N/A
- Revenue This Year
- PIII N/A
- ANTX N/A
- Revenue Next Year
- PIII $9.46
- ANTX N/A
- P/E Ratio
- PIII N/A
- ANTX N/A
- Revenue Growth
- PIII 4.20
- ANTX N/A
- 52 Week Low
- PIII $5.80
- ANTX $0.98
- 52 Week High
- PIII $26.99
- ANTX $1.68
- Technical
- Relative Strength Index (RSI)
- PIII 59.01
- ANTX 61.69
- Support Level
- PIII $8.46
- ANTX $1.22
- Resistance Level
- PIII $8.90
- ANTX $1.33
- Average True Range (ATR)
- PIII 0.32
- ANTX 0.08
- MACD
- PIII -0.02
- ANTX 0.01
- Stochastic Oscillator
- PIII 49.07
- ANTX 82.14
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.